The effect of propolis in diabetic patients

The effect of propolis on glycemic control, Lipid profile, renal function and inflammatory biomarkers in patients with type 2 diabetes mellitus: A randomized double blind clinical Trial.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016092730008N1

Enrollment

100

Registered

2017-09-07

Start date

2016-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Propolis, capsule 500mg, oral, twice daily, 3 month. Intervention 2: Soya, capsules 500mg, oral, twice daily, 3 month.

Treatment - Drugs

Placebo

Propolis, capsule 500mg, oral, twice daily, 3 month

Soya, capsules 500mg, oral, twice daily, 3 month

Eligibility

Sex/Gender

All

Age

25 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 25-80 years; Hemoglobin A1c (HbA1c) Test between 5.9-8%; Fast blood sugar between 126-200 mg/dl; patients were diagnosed less than 10 years; patients should only use oral hypoglycemic agents Exclusion criteria: Pregnancy and lactation; Insulin dependent diabetes; sensivity to honey or bee products; Severe renal or hepatitis failure

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Serum. Timepoint: in the beginning, monthly and in the End of Intervention. Method of measurement: mg/dl with using specific serum kit.;Body Mass Index (BMI). Timepoint: in the beginning and in the End of Intervention. Method of measurement: kg/m2 by measuring height and weight and use of scale.;Blood pressure. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mmHg by using indicator.;2 hours post prandial glucose. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;HbA1C. Timepoint: in the beginning and in the End of Intervention. Method of measurement: % by using specific serum kit.;Triglyceride. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;Cholestrol. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;High Density Lipoprotein (HDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;Low Density Lipoprotein (LDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;Very Low Density Lipoprotein (VLDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;ALANIN AMINOTRANSFERASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;ASPATRTATE AMINOTRANSFERASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;ALKALIN PHOSPHATASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;BLOOD UREA NITROGEN. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;Creatinine.	—

Measure

Time frame

Fasting Blood Serum. Timepoint: in the beginning, monthly and in the End of Intervention. Method of measurement: mg/dl with using specific serum kit.;Body Mass Index (BMI). Timepoint: in the beginning and in the End of Intervention. Method of measurement: kg/m2 by measuring height and weight and use of scale.;Blood pressure. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mmHg by using indicator.;2 hours post prandial glucose. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;HbA1C. Timepoint: in the beginning and in the End of Intervention. Method of measurement: % by using specific serum kit.;Triglyceride. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;Cholestrol. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;High Density Lipoprotein (HDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;Low Density Lipoprotein (LDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;Very Low Density Lipoprotein (VLDL). Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;ALANIN AMINOTRANSFERASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;ASPATRTATE AMINOTRANSFERASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;ALKALIN PHOSPHATASE. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;BLOOD UREA NITROGEN. Timepoint: in the beginning and in the End of Intervention. Method of measurement: mg/dl by using specific serum kit.;Creatinine.

—

Secondary

Measure	Time frame
Sensivity. Timepoint: in the begining, monthly and in the end of intervention. Method of measurement: patient complain, physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Jenabi

School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences

jenabi_maryam@yahoo.com+98 916 634 4139

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026